使用瑞莎珠单抗治疗免疫检查点抑制剂所致小肠结肠炎的症状及超声改善情况 - Suppr

Suppr

超能文献

Symptomatic and Sonographic Improvement of Immune Checkpoint Inhibitor Enterocolitis With Risankizumab.

作者信息

Mei Rena, Pepe Emily, Oh David Y, Tsai Katy K, Chugh Rishika, Kattah Michael G

机构信息

Department of Medicine, University of California San Francisco, San Francisco, CA, USA.

出版信息

Inflamm Bowel Dis. 2025 Apr 10;31(4):1182-1183. doi: 10.1093/ibd/izae259.

DOI:10.1093/ibd/izae259

PMID:39495057

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11985388/

Abstract

摘要

相似文献

Symptomatic and Sonographic Improvement of Immune Checkpoint Inhibitor Enterocolitis With Risankizumab.使用瑞莎珠单抗治疗免疫检查点抑制剂所致小肠结肠炎的症状及超声改善情况

Inflamm Bowel Dis. 2025 Apr 10;31(4):1182-1183. doi: 10.1093/ibd/izae259.

Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives.免疫治疗的胃肠道和肝脏并发症：当前的治疗管理和未来展望。

Curr Gastroenterol Rep. 2020 Mar 17;22(4):15. doi: 10.1007/s11894-020-0752-z.

Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab.接受英夫利昔单抗治疗的皮质类固醇难治性免疫检查点抑制剂诱导性结肠炎患者的临床结局。

J Immunother Cancer. 2021 Jul;9(7). doi: 10.1136/jitc-2021-002742.

Budesonide treatment for microscopic colitis from immune checkpoint inhibitors.布地奈德治疗免疫检查点抑制剂相关显微镜下结肠炎。

J Immunother Cancer. 2019 Nov 7;7(1):292. doi: 10.1186/s40425-019-0756-0.

Immune checkpoint inhibitor-induced colitis is mediated by polyfunctional lymphocytes and is dependent on an IL23/IFNγ axis.免疫检查点抑制剂诱导的结肠炎是由多功能淋巴细胞介导的，并依赖于 IL23/IFNγ 轴。

Nat Commun. 2023 Oct 23;14(1):6719. doi: 10.1038/s41467-023-41798-2.

Systematic review with meta-analysis: effectiveness of anti-inflammatory therapy in immune checkpoint inhibitor-induced enterocolitis.系统评价与荟萃分析：抗炎治疗在免疫检查点抑制剂诱导的肠炎中的疗效。

Aliment Pharmacol Ther. 2020 Nov;52(9):1432-1452. doi: 10.1111/apt.15998. Epub 2020 Sep 13.

Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors.免疫检查点抑制剂治疗后的免疫介导的组织损伤的病理学。

Rheumatology (Oxford). 2019 Dec 1;58(Suppl 7):vii17-vii28. doi: 10.1093/rheumatology/kez465.

Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: A systematic literature review.血管内皮生长因子靶向治疗在免疫检查点抑制剂预处理的肾细胞癌患者中的应用：系统文献回顾。

Cancer Treat Rev. 2024 Jan;122:102652. doi: 10.1016/j.ctrv.2023.102652. Epub 2023 Nov 4.

Reduced Tumor Size of Untreated Papillary Thyroid Carcinoma After Immune Checkpoint Inhibitor-Induced Thyroiditis.免疫检查点抑制剂诱导的甲状腺炎后未经治疗的乳头状甲状腺癌肿瘤大小减小

AACE Clin Case Rep. 2023 Jun 3;9(5):162-165. doi: 10.1016/j.aace.2023.05.009. eCollection 2023 Sep-Oct.

Management Considerations for Immune Checkpoint Inhibitor-Induced Enterocolitis Based on Management of Inflammatory Bowel Disease.基于炎症性肠病治疗的免疫检查点抑制剂相关性肠炎的管理考虑

Inflamm Bowel Dis. 2020 Apr 11;26(5):662-668. doi: 10.1093/ibd/izz212.

本文引用的文献

Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis.免疫相关肠炎患者的免疫检查点抑制和选择性免疫抑制治疗的联合应用。

J Immunother Cancer. 2023 Jun;11(6). doi: 10.1136/jitc-2023-007195.

Microbiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitor-induced colitis.粪便微生物移植通过改变微生物组对难治性免疫检查点抑制剂诱导的结肠炎有效。

Sci Transl Med. 2023 Jun 14;15(700):eabq4006. doi: 10.1126/scitranslmed.abq4006.

Characteristics and usefulness of transabdominal ultrasonography in immune-mediated colitis.经腹超声检查在免疫介导性结肠炎中的特征及应用价值

Intest Res. 2023 Jan;21(1):126-136. doi: 10.5217/ir.2021.00166. Epub 2022 Jul 22.

Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study.免疫介导性腹泻和结肠炎在癌症患者中的 vedolizumab 和英夫利昔单抗治疗的疗效和安全性：一项两中心观察性研究。

J Immunother Cancer. 2021 Nov;9(11). doi: 10.1136/jitc-2021-003277.

Ustekinumab for Refractory Colitis Associated with Immune Checkpoint Inhibitors.优特克单抗用于治疗与免疫检查点抑制剂相关的难治性结肠炎。

N Engl J Med. 2021 Feb 11;384(6):581-583. doi: 10.1056/NEJMc2031717.

Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis.比较维得利珠单抗与肿瘤坏死因子拮抗剂治疗溃疡性结肠炎的安全性和有效性。

Clin Gastroenterol Hepatol. 2022 Jan;20(1):126-135. doi: 10.1016/j.cgh.2020.10.003. Epub 2020 Oct 8.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验